Genetic Testing

Expert Q&A

Pharmacogenetics: Not Quite Ready for Prime Time?

Topics: Chromosomal Microarray | CYP2C19 | CYP2D6 | Fragile X | Genetic Testing | MTHFR | Pharmacogenomics | Whole Genome Sequencing

CCPR: Welcome, Dr. Besterman. Please tell us who you are and where you work. Dr. Besterman: I’m an adult and child & adolescent psychiatrist at the Rady Children’s Hospital inpatient child and adolescent unit in San Diego, and I’m a clinical investigator at the Rady Children’s Institute for Genomic Medicine studying psychiatric genetics.

Read More
Research Update

Genetic Testing in Depression

Topics: GeneSight | Genetic Testing | Genetics and Psychiatry | Pharmacogenomics | Randomized controlled trial | Research | Research Update

REVIEW OF: Perlis RH et al, Depress Anxiety 2020;37(9):834–841 STUDY TYPE: Randomized controlled trial By tailoring medications to a patient’s genetic profile, pharmacogenomics promises less medication trial and error, fewer side effects, and better overall outcomes. But does knowing a patient’s pharmacogenetic profile really improve treatment f

Read More
Expert Q&A

Genetic Testing: What You Need to Know in 2021

Topics: Autism Spectrum Disorder | CYP2C19 | CYP2D6 | GeneSight | Genetic Testing | Genetics and Psychiatry | Laboratory Testing in Psychiatry | Learning & Developmental Disabilities | Pharmacogenomics | Treatment-Resistant Depression | Whole Genome Sequencing

TCPR: Is there a role for genetic testing in clinical practice? Dr. Nurnberger: I think the evidence is growing that there’s a place for this in clinical practice. The meta-analyses of pharmacogenetic tests are actually looking pretty favorable recently, at least for some genes, particularly CYP2D6 and 2C19 (Bousman CA et al, Pharmacogenomics 2019;20

Read More
Article

A Second Look at Genetic Testing

Topics: Free Articles | GeneSight | Genetic Testing | Pharmacology

Genetic tests are marketed with a bold claim: that a handful of genes can predict medication response. AssureRx’s GeneSight is the most popular of these tests, and in 2015 we reviewed the evidence behind its panel. In short, it was lacking, but the company has just released new data that may move it a little closer to the mainstream. What’s

Read More